Summit Therapeutics (Nasdaq:SMMT) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

SMMT 주식 개요

서밋 테라퓨틱스는 바이오 제약 회사로 미국과 영국에서 환자, 의사, 간병인 및 사회 친화적인 의학적 치료법의 발견, 개발 및 상용화에 주력하고 있습니다.

SMMT 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

위험 분석

지난 5년간 매년 수익이 61.2% 씩 감소했습니다.

수익이 1백만 달러 미만인 경우 ( $0 )

최근 3개월간 주가 변동폭 심해

Summit Therapeutics Inc. 경쟁사

CRISPR Therapeutics

NasdaqGM:CRSP

US$4.6b

Blueprint Medicines

NasdaqGS:BPMC

US$6.7b

Revolution Medicines

NasdaqGS:RVMD

US$6.4b

SpringWorks Therapeutics

NasdaqGS:SWTX

US$2.8b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Summit Therapeutics
과거 주가
현재 주가	US$7.80
52주 최고치	US$11.25
52주 최저치	US$1.52
베타	-1.03
11개월 변경	-10.19%
3개월 변경 사항	95.98%
1년 변경 사항	210.76%
33년 변화	0.65%
5년 변화	504.65%
IPO 이후 변화	-24.20%

최근 뉴스 및 업데이트

Summit Therapeutics Stock: Plunging Despite A Win?

May 31

Recent updates

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Aug 17

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Aug 11

Summit to explore additional trial for its bacteria-induced colon infection drug

Jul 14

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Apr 29

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Dec 23

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Jun 22

Summit Therapeutics to join Russell 3000 Index

Jun 08

주주 수익률

	SMMT	US Biotechs	US 마켓
7D	-1.6%	-0.7%	0.07%
1Y	210.8%	10.2%	20.7%

수익률 대 산업: SMMT 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: SMMT 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is SMMT's price volatile compared to industry and market?
SMMT volatility
SMMT Average Weekly Movement	79.2%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.8%

안정적인 주가: SMMT 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: SMMT 의 주간 변동성은 지난 1년 동안 41% 에서 80% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
2003	105	Bob Duggan	www.summittxinc.com

서밋 테라퓨틱스는 바이오 제약 회사로 미국과 영국에서 환자, 의사, 간병인 및 사회 친화적인 의학적 치료법의 발견, 개발 및 상용화에 주력하고 있습니다. 이 회사의 주요 개발 후보물질은 항혈관신생을 통해 PD-1을 차단하는 면역 치료용 이중특이성 항체인 이보네시맙이며, 항감염제 포트폴리오에는 주로 카바페넴 내성 장내세균 감염을 포함한 다제내성 감염 치료를 위한 새로운 계열의 정밀 항생제인 SMT-738이 포함되어 있습니다. 이보네시맙의 개발 및 상용화를 위해 아케소 및 그 계열사와 협력 및 라이선스 계약을 체결했습니다.

Summit Therapeutics Inc. 기본 사항 요약

Summit Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
SMMT 기본 통계
시가총액	US$5.48b
수익(TTM)	-US$116.02m
수익(TTM)	n/a

0.0x

P/S 비율

-47.2x

P/E 비율

SMMT 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
SMMT 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$116.03m
수익	-US$116.02m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.17
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	226.2%

SMMT 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

SMMT 주식 개요

보상

위험 분석

Summit Therapeutics Inc. 경쟁사

NasdaqGM:CRSP

US$4.6b

NasdaqGS:BPMC

US$6.7b

NasdaqGS:RVMD

US$6.4b

NasdaqGS:SWTX

US$2.8b

가격 내역 및 성능

최근 뉴스 및 업데이트

Summit Therapeutics Inc. Appoints Jeff Huber to Its Board of Directors

Summit Therapeutics Inc. announced that it has received $199.999998 million in funding from Baker Bros. Advisors LP

Summit Therapeutics Inc. announced that it expects to receive $199.999998 million in funding from Baker Bros. Advisors LP

Summit Therapeutics Inc. Announces Phase III Clinical Trial, HARMONI-2 or AK112-303 Met its Primary Endpoint of Progression-Free Survival

Summit Therapeutics Stock: Plunging Despite A Win?

Summit Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $90 million.

Recent updates

Summit Therapeutics Inc. Appoints Jeff Huber to Its Board of Directors

Summit Therapeutics Inc. announced that it has received $199.999998 million in funding from Baker Bros. Advisors LP

Summit Therapeutics Inc. announced that it expects to receive $199.999998 million in funding from Baker Bros. Advisors LP

Summit Therapeutics Inc. Announces Phase III Clinical Trial, HARMONI-2 or AK112-303 Met its Primary Endpoint of Progression-Free Survival

Summit Therapeutics Stock: Plunging Despite A Win?

Summit Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $90 million.

New major risk - Share price stability

Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer

Summit Therapeutics Inc., Annual General Meeting, Jun 14, 2024

Summit Therapeutics Inc. to Report Q1, 2024 Results on May 01, 2024

Less than half of directors are independent

Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors

Summit Therapeutics Inc. Appoints Bhaskar Anand as Chief Accounting Officer, Head of Finance, to Serve as Its Principal Accounting Officer

Co-CEO, President & Director recently bought US$411k worth of stock

Summit Therapeutics Inc. Announces Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

Summit Therapeutics Inc. Announces That Data for Its Novel, Potential First-In-Class Investigational Bispecific Antibody, Ivonescimab, Will Be Presented At the 2024 European Lung Cancer Congress (Elcc 2024) in Prague, Czech Republic

New minor risk - Financial position

Summit Therapeutics Inc. to Report Q4, 2023 Results on Feb 20, 2024

Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress

Summit Therapeutics Announces Updated Phase II Data for Ivonescimab At 42Nd Annual J.P. Morgan Healthcare Conference

Co-CEO, President & Director exercised options to buy US$2.1m worth of stock.

Laura Chow Joins Summit Therapeutics Inc. as Senior Vice President of Clinical Development

Summit Therapeutics Inc. to Report Q3, 2023 Results on Nov 07, 2023

Lead Independent Director recently bought US$5.0m worth of stock

Summit Therapeutics Inc. Announces Executive Changes

First half 2023 earnings released: US$1.03 loss per share (vs US$0.38 loss in 1H 2022)

Summit Therapeutics Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Share price stability

First quarter 2023 earnings released: US$1.43 loss per share (vs US$0.22 loss in 1Q 2022)

Summit Therapeutics Announces First Patient Treated in Phase III Harmoni Clinical Trial Evaluating Ivonescimab (SMT112)

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (Smt112)

Summit Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.41 loss per share (vs US$0.96 loss in FY 2021)

Summit Therapeutics Inc. Appoints Yu (Michelle) Xia as Member of the Board

We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Summit Therapeutics Inc. Appoints Alessandra Cesano to Its Board of Directors

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.20 loss in 3Q 2021)

Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole

Summit Therapeutics Inc. Announces Executive Changes

Summit Therapeutics slips on plans to terminate study for lead candidate

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.27 loss in 2Q 2021)

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Summit Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $99.91 million.

Summit Therapeutics Appoints Maky Zanganeh as Co-CEO

Summit Therapeutics Provides Update on Ridinilazole

Summit to explore additional trial for its bacteria-induced colon infection drug

Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell 2000 Growth Index

Summit Therapeutics Inc. Appoints Ankur Dhingra as Chief Financial Officer

First quarter 2022 earnings released: US$0.22 loss per share (vs US$0.21 loss in 1Q 2021)

Summit Therapeutics Inc., Annual General Meeting, Jun 15, 2022

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Less than half of directors are independent

Less than half of directors are independent

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Summit Therapeutics Inc. Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection

Summit Therapeutics Inc. Provides Update on Ri-CoDIFy Trials

Summit Therapeutics Presents Research Data from Phase II Studies, Including Evidence Validating Microbiome Preservation, for Its Investigational Drug Ridinilazole